This review concluded that there were significant benefits in overall survival and progression-free survival with longer duration regimens of chemotherapy compared with shorter duration regimens in patients with metastatic breast cancer. The unknown quality of the included trials and comparisons between different treatments in the trials mean that the authors' conclusions should be interpreted with caution.
Searching
MEDLINE, Web of Science, EMBASE and the Cochrane Library were searched to the end of April 2010 for relevant studies; search terms were reported. Reference lists of published trials, review abstracts and editorials on chemotherapy in metastatic breast cancer were scanned to identify additional studies. Abstracts from meetings and the United States National Cancer Institute were searched for trials. It was unclear if language restrictions were applied to the search.
Study selection
Randomised controlled trials (RCTs) of patients with metastatic breast cancer that evaluated the effect of duration of first-line chemotherapy regimens on overall survival and progression-free survival were eligible for inclusion. Eligible trials compared short versus long duration of chemotherapy: fixed number of treatment cycles versus continuation of the same treatment until disease progression; fixed number of treatment cycles versus larger fixed number of cycles using identical treatments; and fixed number of initial chemotherapy cycles compared with an identical regimen followed by additional cycles of an alternative chemotherapy. All interventions that involved single agents and combination regimens were included, as were trials which permitted concomitant endocrine therapy in both treatment arms. Trials that compared differing treatment regimens, and those that evaluated high-dose chemotherapy with peripheral blood stem cell support were excluded.
The included trials were conducted from 1987 to 2010. The number of chemotherapy cycles in the control groups of shorter treatment duration ranged from three to eight cycles. Numbers of cycles in the longer treatment duration groups ranged from a minimum of six cycles to continuation of treatment until disease progression or the onset of unacceptable toxicity. The chemotherapeutic agents used were doxorubicin, cyclophosphamide, methotrexate, fluorouracil, epirubicin, vincristine, mitoxantrone, mitomycin, prednisone, tamoxifen, halotestin, paclitaxel, and pegylated liposomal doxorubicin (in a range of combinations). Concomitant tamoxifen was administered in a few trials until disease progression in intervention and control groups.
Four reviewers independently performed the study selection; any disagreements were resolved by consensus.
Assessment of study quality
The authors did not state that they assessed methodological quality.
Data extraction
Data were extracted or estimated indirectly from event numbers, p-values from log-rank tests, or from survival curves to calculate log hazard ratios (HR) and 95% confidence intervals (CI) for progression-free survival and overall survival. When necessary, the reviewers also contacted the principal investigators of the included studies to retrieve missing information.
Four reviewers performed the data extraction; all extracted data were internally checked for consistency.
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Methods of synthesis
Pooled hazard ratios and 95% confidence intervals were calculated using a fixed-effect model. Heterogeneity was evaluated using χ 2 and I 2 . If statistically significant heterogeneity was present, the results were pooled using a randomeffects model. Subgroup analyses were conducted on the time of random assignment (before versus after first line chemotherapy), the type of prolonged chemotherapeutic intervention, the number of treatment cycles in the shorter duration arms of the trials (below 6 versus 6 or more), and the co-administration of endocrine therapy. Sensitivity analyses were conducted to examine the extent by which individual trials influenced the pooled estimates by consecutively omitting every trial from the meta-analysis.
Publication bias was evaluated by visual appraisal of funnel plots and using the Begg and Eggers's tests.
Results of the review
Eleven trials (n=2,269 patients) were included in the review. At follow-up, data were collected from 88.5 to 100% of the randomised patients. The maximum follow-up in the trials ranged from 18 to 120 months. Random assignment was undertaken before induction of chemotherapy in four trials; in the remaining trials, randomisation occurred after the start of first-line chemotherapy.
Statistically significant survival benefits were observed in overall survival in metastatic breast cancer with longer durations of chemotherapy treatment (HR 0.91, 95% CI 0.84 to 0.99, I 2 =0; 11 trials) compared with shorter durations of chemotherapy treatment. There were no significant differences observed in overall survival in the subgroup analyses.
There were statistically significant increases in progression-free-survival observed with longer durations of chemotherapy (HR 0.64, 95% CI 0.55 to 0.76; 11 trials) with substantial heterogeneity (I 2 =68%). Further analysis found that the results of one trial (n=290) accounted for most of the heterogeneity. There were no significant differences in progression-free survival observed in the subgroup analyses.
Visual appraisal of the funnel plots and the results of the Egger and Begg tests did not show any evidence of publication bias
Authors' conclusions
Longer duration of first-line chemotherapy was associated with clinically modest but statistically significant improvements in overall survival, and clinically meaningful and statistically significant improvements in progressionfree survival in patients with metastatic breast cancer.
CRD commentary
The review addressed a clear question. Criteria for the inclusion of studies were defined. Appropriate databases were searched for relevant studies and there were some attempts to identify unpublished studies. Steps were taken to reduce errors and bias in the performance of study selection and data extraction.
There was no assessment of methodological quality, which meant that it was difficult to determine the reliability of the results. It was unclear if the decision to combine the results statistically in a meta-analysis was justified, given the heterogeneity in chemotherapeutic regimens and follow-up periods. Hazard ratios were calculated using the manipulation of some data, which may have introduced some errors. Most trials examined different treatment durations in different chemotherapy combinations, which meant that some of the differences observed between the groups may be due to the different therapies used rather than only the different number of cycles in the long-duration group. The reviewers acknowledged some of the limitations of the review including the heterogeneity of trial designs and chemotherapeutic regimens, publication status and the relatively small numbers of trials and patients. In addition, the reviewers also highlighted that some of the chemotherapy regimens used in the earlier included trials were outdated and probably inferior to currently available treatments.
The lack of information about the quality of the included trials and the comparison of different treatment durations
